High-dose etoposide in allogeneic stem cell transplantation Øystein BruserudHåkon ReikvamKimberley Joanne Hatfield Review Article 06 October 2012 Pages: 765 - 782
Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer Takayuki ShiroyamaTakashi KijimaAtsushi Kumanogoh Original Article 09 September 2012 Pages: 783 - 789
Phase I study of nelfinavir in liposarcoma Janet PanMichelle MottWarren A. Chow Original Article 16 September 2012 Pages: 791 - 799
Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro Chongmei HuangXiaoxia HuJianmin Yang Original Article 21 September 2012 Pages: 801 - 809
Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models Daniela MecoAngela Maria Di FrancescoRiccardo Riccardi Original Article 25 September 2012 Pages: 811 - 822
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment L. A. DevrieseP. O. WitteveenJ. H. M. Schellens Original Article 26 September 2012 Pages: 823 - 832
6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation Wesam M. El-BaklyManal L. LoukaMona F. Schaalan Original Article 27 September 2012 Pages: 833 - 841
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy Michael J. PishvaianRebecca SlackJohn L. Marshall Original Article 27 September 2012 Pages: 843 - 853
Clinical activity of mTOR inhibition in combination with cyclophosphamide in the treatment of recurrent unresectable chondrosarcomas Rinat Bernstein-MolhoYehuda KollenderOfer Merimsky Original Article 28 September 2012 Pages: 855 - 860
Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials Man-Tang QiuXiang-Xiang DingLin Xu Original Article 28 September 2012 Pages: 861 - 873
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer Andrew H. KoThach-Giao TruongMargaret A. Tempero Original Article 28 September 2012 Pages: 875 - 881
Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer M. ProvencioC. CampsR. Rosell Original Article 29 September 2012 Pages: 883 - 890
Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies Da ZhangMonica MitaPaul Statkevich Clinical Trial Report 09 October 2012 Pages: 891 - 898
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer Marta LucchettaSara LonardiHaralabos P. Kalofonos Short Communication 30 October 2012 Pages: 899 - 902
